Please login to the form below

Not currently logged in
Email:
Password:

Merck completes €15m Spanish biotech facility expansion

Enlarged Tres Cantos site will help meet demand for fertility and growth hormone drugs
Merck

Merck has completed a €15m investment project at its biotech facility in Spain that will allow it to up production of its fertility and growth hormone disorder treatments by 50%.

The German company said it would also be increasing the number of staff it employs at the facility by 20% thanks to the two-year programme.

The Tres Cantos plant is Merck's main site for the production of active substances in its fertility treatment Gonal-f and endocrine and metabolic disorders treatment Saizen, for which global demand is rising steadily.

Simon Sturge, chief operating officer of Merck's biopharma business, said: “The demand for our core portfolio of medicines keeps increasing worldwide.

“The expansion in Tres Cantos is part of our continuous commitment to deliver high quality medicines at the right time to our patients.”

Merck was able to raise its sales forecast for 2016 earlier this year after a particularly strong second quarter performance, spearheaded by a 23% growth of Gonal-f that saw its sales reach €209m.

The Darmstadt, Germany-headquartered firm has invested around €250m in its healthcare manufacturing network so far this year, including in a new regional hub in Côte d'Ivoire launched just this week.

The hub will serve Merck's operations in French-speaking countries in Central and West Africa, and will oversee two minilabs donated by the company to aid in the region's fight against counterfeit medicines.

Thierry Hulot, head of Merck's biopharma global manufacturing and supply, commented: “We are continuously investing in our manufacturing network to maintain state-of-the-art industry level and adapt its capacity to patient needs for our medicines.

“We are very pleased to have completed the expansion of our Tres Cantos biotech manufacturing facility which plays a leading role in our manufacturing network and exemplifies our culture of safety at work, quality and service.”

Article by
Rebecca Clifford

18th October 2016

From: Research, Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....